Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | ACP1 | P24666 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2566348 | 0.79 | CYP11B1 (0.53) | GAAALDH1A1CYP11B1CYP11B2LMNA | |
| SCHEMBL9714248 | 0.78 | LMNA (0.55) | MEN1KMT2AGAABRD4ACP1 | |
| SCHEMBL9714543 | 0.78 | LMNA (0.55) | MEN1KMT2AGAABRD4ACP1 | |
| SCHEMBL10769703 | 0.76 | GAA (0.44) | MEN1KMT2AGAAACP1ALDH1A1 | |
| SCHEMBL3733246 | 0.75 | CYP19A1 (0.54) | MEN1KMT2ABRD4ALDH1A1CYP11B1 | |
| SCHEMBL10566878 | 0.75 | ALDH1A1 (0.52) | MEN1KMT2AGAAACP1ALDH1A1 | |
| SCHEMBL10570732 | 0.75 | ALDH1A1 (0.52) | MEN1KMT2AGAAACP1ALDH1A1 | |
| SCHEMBL20428044 | 0.74 | CYP11B1 (0.55) | MEN1KMT2ABRD4ACP1ALDH1A1 | |
| SCHEMBL7215799 | 0.73 | CYP11B1 (0.67) | MEN1KMT2AGAABRD4ALDH1A1 | |
| SCHEMBL6154837 | 0.71 | ALDH1A1 (0.48) | MEN1KMT2AGAABRD4ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229076-A1 | Substituted imidazoles as selective modulators of bradykinin B2 receptors | RACHWAL STANISLAW (US) | 2003-12-11 | — | — | US | disclosed |
| US-6509366-B2 | Substituted imidazoles as selective modulators of Bradykinin B2 receptors | NEUROGEN CORPORATION | 2003-01-21 | — | — | US | disclosed |
| US-6482844-B1 | 1-benzylimidazole derivatives | NEUROGEN CORPORATION | 2002-11-19 | — | — | US | disclosed |
| US-20020115693-A1 | Substituted imidazoles as selective modulators of bradykinin B2 receptors | NEUROGEN CORPORATION | 2002-08-22 | — | — | US | disclosed |
| WO-2001056995-A1 | SUBSTITUTED IMIDAZOLES AS SELECTIVE MODULATORS OF BRADYKININ B2 RECEPTORS | NUEROGEN CORPORATION (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229076-A1 | Substituted imidazoles as selective modulators of bradykinin B2 receptors | BDKRB2, BDKRB1, KISS1R | MEN1 44/4885KMT2A 3452/4885GAA 4131/4885 |
| US-20020115693-A1 | Substituted imidazoles as selective modulators of bradykinin B2 receptors | BDKRB2, BDKRB1, KISS1R | MEN1 37/4885KMT2A 3490/4885GAA 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.